US stock · Healthcare sector · Diagnostics & Research

CareDx, Inc

CDNA

NASDAQ

7.98

USD

-0.15

(-1.85%)

After Hours Market

-5.40P/E

-10Forward P/E

-0.22P/E to S&P500

429.269MMarket CAP

- -Div Yield

Summary Financials Transcripts Monitoring Classic View

Upcoming Earnings

2 Aug-7 Aug

Shares Short

5/15/23

6.2M

Short % of Float

15.03%

Short % of Shares Outs.

11.53%

% Held by Insiders

3.98%

% Held by Institutions

107.77%

Beta

1.03

PEG Ratio

-0.40

52w. high/low

27.35/6.22

Avg. Daily Volume

1.13M

Return %

Stock

S&P 500

1 year

(68.69)

3.92

3 years

(75.75)

37.48

5 years

(39.24)

56.99

Scale: |

High

Low

- -

10.89

5.40

8.00

3.70

6.84

2.50

7.98

0.76

30.80

4.92

41.27

18.75

79.92

13.04

99.83

39.16

47.82

10.68

18.04

6.22

Currency: USD

- -

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

2022

TTM

Revenue per share

- -

2.77

3.00

4.70

2.37

2.46

2.07

2.15

3.01

4.13

5.63

6.03

5.98

Earnings per share

- -

(0.69)

(0.48)

0.13

(1.16)

(2.39)

(2.38)

(1.31)

(0.52)

(0.40)

(0.58)

(1.44)

(1.51)

FCF per share

- -

(0.26)

(0.09)

(0.70)

(0.92)

(1.03)

(0.62)

(0.32)

(0.15)

0.50

(0.75)

(0.87)

(0.40)

Dividends per share

- -

CAPEX per share

- -

0.02

0.01

0.13

0.10

0.03

0.01

0.20

0.08

0.22

0.38

0.40

0.35

Book Value per sh.

- -

(19.97)

(20.44)

7.10

2.49

1.18

(0.26)

2.69

2.35

5.97

8.84

8.08

8.09

Comm.Shares outs.

- -

Avg. annual P/E ratio

- -

60.0

(5.1)

(1.9)

(1.3)

(11.9)

(54.5)

(87.1)

(122.0)

(18.2)

(5.4)

P/E to S&P500

- -

3.3

(0.3)

(0.1)

(0.5)

(2.2)

(2.3)

(4.1)

(0.9)

(0.2)

Avg. annual div. yield

- -

Revenue (m)

- -

127

192

296

322

320

Operating margin

- -

(11.5)%

(3.9)%

4.6%

(42.4)%

(91.9)%

(42.0)%

(20.3)%

(19.3)%

(11.7)%

(10.0)%

(24.0)%

(25.9)%

Depreciation (m)

- -

Net profit (m)

- -

(5)

(4)

(14)

(39)

(55)

(47)

(22)

(19)

(31)

(77)

(81)

Income tax rate

- -

208.6%

- -

3.9%

3.0%

8.3%

5.2%

4.4%

(0.5)%

(0.7)%

Net profit margin

- -

(24.7)%

(16.0)%

2.9%

(48.7)%

(97.1)%

(114.8)%

(61.1)%

(17.3)%

(9.7)%

(10.3)%

(23.8)%

(25.3)%

Working capital (m)

- -

(14)

(16)

204

356

312

300

Long-term debt (m)

- -

Equity (m)

- -

(147)

(151)

(6)

278

466

431

420

ROIC

- -

(68.5)%

(61.1)%

(3.0)%

(26.6)%

(105.8)%

(123.0)%

(38.8)%

(18.8)%

(6.3)%

(16.4)%

(18.2)%

Return on capital

- -

(23.9)%

(14.1)%

2.3%

(21.8)%

(51.3)%

(61.5)%

(34.0)%

(15.8)%

(5.4)%

(5.7)%

(14.0)%

(15.6)%

Return on equity

- -

3.4%

2.4%

1.9%

(46.5)%

(202.6)%

904.3%

(48.7)%

(22.2)%

(6.7)%

(6.6)%

(17.8)%

(19.2)%

Plowback ratio

- -

100.0%

Div.&Repurch./FCF

- -

961.2%

- -

Capital Structure

10 May · 2023 | Q1

All numbers in millions

Total liabilities

$ 108

Total assets

$ 528

Long-term debt

$ 32

Cash and equiv.

$ 75

Goodwill

$ 40

Retained earnings

$ (485)

Common stock

Enterprise Value

$ 387

Working Capital

Currency: USD, in millions

2020

2021

2022

Cash & Investments

225

348

293

Receivables

Inventory

Other

222

(36)

Current assets

273

433

388

Acc. Payable

Debt due

- -

Other

Current liabilities

Annual growth rates

(avg. rate of change)

1 year

5 years

10 years

Revenue

8.57%

45.00%

36.49%

Cash flow

17.50%

(194.16)%

(6.23)%

Earnings

149.86%

36.47%

(179.83)%

Dividends

- -

Book value

(7.51)%

60.99%

(193.48)%

Insider Trading

Type

Date

Seeto Reginald

Sale

2,819

06/02/23

Jain Abhishek

InKind

1,297

05/26/23

Seeto Reginald

Sale

2,819

05/02/23

Jain Abhishek

InKind

221

04/18/23

Maag Peter

Award

1,256

04/11/23

Quarterly Revenue

Currency: USD, in millions

Year

Total

2021

296

2022

322

2023

- -

Earnings per share

Currency: USD

Year

Total

2021

(0.01)

(0.04)

(0.23)

(0.31)

(0.58)

2022

(0.37)

(0.41)

(0.32)

(0.34)

(1.44)

2023

(0.44)

- -

Quarterly dividends paid

Currency: USD

Year

Total

2021

- -

2022

- -

2023

- -

Company Description

Sector:

Healthcare

Industry:

Diagnostics & Research

CEO:

Dr. Reginald Seeto M.D., MBBS

Full-time employees:

727

City:

South San Francisco

Address:

1 Tower Place

IPO:

Jul 17, 2014

CIK:

0001217234

Website:

caredx.com

CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Powered by AI

CareDx, Inc

7.98